As Neurocrine Biosciences Inc. closed the book on its DHEA program to treat Alzheimer's disease, the company said it was neither surprised nor disappointed by last week's failed Phase II/III study. The development of the compound was being funded by an affiliate and NBIX said it never assumed that the compound would succeed.

Previous studies, although not powered for statistical significance, had suggested efficacy of DHEA in treating Alzheimer's. The agent (dehydroepiandrosterone) is thought to act